DBV Technologies (NASDAQ:DBVT) Major Shareholder Bpifrance Epic Sells 1,292,103 Shares of Stock

DBV Technologies S.A. (NASDAQ:DBVT) major shareholder Bpifrance Epic sold 1,292,103 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the transaction, the insider directly owned 7,303,369 shares in the company, valued at $30,601,116.11. This trade represents a 15.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bpifrance Epic also recently made the following trade(s):

• On Wednesday, December 17th, Bpifrance Epic sold 2,076,990 shares of DBV Technologies stock. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50.

DBV Technologies Price Performance

DBVT opened at $22.76 on Friday. The stock’s 50 day simple moving average is $15.38 and its 200 day simple moving average is $11.83. The firm has a market cap of $914.04 million, a price-to-earnings ratio of -4.40 and a beta of -1.10. DBV Technologies S.A. has a 1 year low of $2.92 and a 1 year high of $26.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the second quarter worth $9,659,000. MPM Bioimpact LLC bought a new position in DBV Technologies in the second quarter worth $9,649,000. Octagon Capital Advisors LP bought a new position in DBV Technologies in the second quarter worth $9,315,000. Finally, Millennium Management LLC lifted its position in DBV Technologies by 26.1% during the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after buying an additional 69,849 shares during the period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research report on Thursday. Citizens Jmp boosted their price target on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday. Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Guggenheim reissued a “buy” rating and set a $51.00 target price (up from $35.00) on shares of DBV Technologies in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $35.38.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: Phase‑III win in peanut allergy improves commercial/clinical outlook — a Bioworld report says DBV’s VIT® program delivered a positive Phase III result, a material de‑risking event for a lead program that can drive future revenue and re‑rating. Vitesse finesse pays off: DBV wins in peanut allergy phase III
• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts, signaling stronger long‑term profitability expectations (FY2027–FY2029 upgrades). That upward revision likely helped investor sentiment and price momentum. HC Wainwright Expects Stronger Earnings for DBV Technologies
• Positive Sentiment: Additional bullish analyst notes and coverage changes — the stock was reported to hit a new 1‑year high after analyst upgrades, and coverage consensus sits around a “Moderate Buy,” with at least one firm (Citizens JMP) forecasting strong price appreciation. Those actions typically boost retail/institutional interest. DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Market consensus EPS remains deeply negative for the current year (consensus ~($7.05) EPS), so while upgrades are meaningful, the company is still transitioning from loss‑making to profitable — investors should watch upcoming milestones and cash runway closely.
• Negative Sentiment: Major shareholder Bpifrance Epic sold large blocks of stock on Dec 17–18 (combined ~3.37M shares sold across two days, materially reducing its stake). Large insider/major‑holder selling can pressure the stock and signal liquidity‑driven exits even when fundamentals improve. SEC filing: Bpifrance Epic Insider Sales SEC Filing
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (worse near‑term profitability view), a reminder that boutique analysts still see near‑term execution and cash burn risk — this can cap upside until revenue/profitability is proven.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.